ITOVEBI

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Italy, Lithuania, Romania.

Active ingredients

The drug ITOVEBI contains one active pharmaceutical ingredient (API):

1	Inavolisib UNII L4C1UY2NYH - INAVOLISIB
	Inavolisib is an inhibitor of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha isoform protein (p110α; encoded by the PIK3CA gene). In addition, inavolisib promotes the degradation of mutated p110α (mutant degrader). The PI3K signalling pathway is commonly dysregulated in HR-positive breast cancer, often due to activating PIK3CA mutations. With its dual mechanism of action, inavolisib inhibits the activity of downstream PI3K pathway targets, including AKT, resulting in reduced cellular proliferation and induction of apoptosis in PIK3CA-mutated breast cancer cell lines.
	Read more about Inavolisib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ITOVEBI Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
ITOVEBI Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EM06		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
Discover more medicines within L01EM06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3133471, 3133482
FR	Base de données publique des médicaments	61001565, 68964635
IT	Agenzia del Farmaco	052380019, 052380021
LT	Valstybinė vaistų kontrolės tarnyba	1104264, 1104265
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W71306001, W71307001
US	FDA, National Drug Code	50242-079, 50242-084